Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Journey Medical CorporationNASDAQ: DERM
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income dips below year-ago levels
Q1 FY2026 net income of $2.23M (cash outflow) fell 45.2% year over year, behind the +15.5% change in trailing-twelve-month net income. Sequentially, it rose 78.8% from the prior quarter. Over 3 fiscal years it compounded at -27.2% a year.
Context
- Net income amounted to 18.5% of revenue in FY2025, down 7.7 pp from a year earlier.
- Net income grew in size in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of -$3.9M (-65.9%) for the fiscal year ending Dec 2026, a slowdown from the -22.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.23M+78.8% QoQ
- Last fiscal yearDec 2025
- -$11.43M-22.1% YoY
- LTMMar 2026
- -$9.59M+15.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -45.2% | -83.4% | -38.1 pp |
| 1 year | -22.1% | -65.9% | -43.8 pp |
| 3-year CAGR | -27.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (11.43M) USD
- Year-over-year change
- +22.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.43M) | +22.1% |
| FY2024 | 2024-12-31 | (14.67M) | -280.8% |
| FY2023 | 2023-12-31 | (3.85M) | +87.0% |
| FY2022 | 2022-12-31 | (29.63M) | +32.7% |
| FY2021 | 2021-12-31 | (43.99M) | — |
Net Income vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.5% is the 7th highest of 10, against a peer median of +24.9%.
- Net income amounts to 14.8% of revenue for DERM, versus a peer median of 180.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €340.16M EUR | +84.7% | +84.4% | 7587.8% | |
| LTM Mar 2026 | $151.77M USD | +296.2% | — | 8550.6% | |
| LTM Mar 2026 | $136.85M USD | +947.5% | +42.7% | 1427.2% | |
| LTM Mar 2026 | €83.7M EUR | +24.9% | +44.2% | 512.9% | |
| LTM Mar 2026 | $71.83M USD | +124.8% | -84.4% | 63.6% | |
| LTM Mar 2026 | $54.64M USD | -17.6% | +16.2% | 167.0% | |
| LTM Mar 2026 | $26.1M USD | +23.0% | +6.8% | 180.3% | |
| LTM Mar 2026 | CA$25.23M CAD | -249.4% | — | 9.2% | |
| LTM Mar 2026 | $9.59M USD | +15.5% | -27.2% | 14.8% | |
| LTM Mar 2026 | $8.38M USD | -42.0% | -24.3% | 16.4% | |
| Peer median (excluding DERM) | — | +24.9% | +16.2% | 180.3% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.99M) | (29.63M) | (3.85M) | (14.67M) | (11.43M) |
| Depreciation & Amortization | 2.56M | 4.37M | 3.86M | 3.42M | 4.72M |
| Deferred Income Tax | 1.57M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.47M | 4.43M | 2.61M | 6.1M | 6.29M |
| Change in Working Capital | 14.71M | 6.19M | (1.66M) | (3.77M) | (11.9M) |
| Accounts Receivables | 768K | (5.38M) | 12.55M | 4.48M | (19.34M) |
| Inventory | (8.46M) | 1.74M | 3.95M | (4.23M) | 4.81M |
| Accounts Payables | 21.71M | 14.34M | (18.42M) | (2.1M) | (7.27M) |
| Other Working Capital | 686K | (4.52M) | 262K | (1.92M) | 9.91M |
| Other Non-Cash Items | 20.51M | 1.12M | 4.29M | (211K) | (123K) |
| Operating Cash Flow | (2.18M) | (13.53M) | 5.24M | (9.13M) | (12.44M) |
| Capital Expenditures | (10M) | (20M) | (5M) | (15M) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (10M) | (20M) | (5M) | (15M) | 0 |
| Debt Repayment | 5.05M | 16.9M | (8.95M) | 8.7M | 15.73M |
| Common Stock Issued | 32.54M | 142K | 4.49M | 8.29M | 16.93M |
| Common Stock Repurchased | 0 | (371K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 16.97M | (214K) | (350K) | (50K) | (16.43M) |
| Financing Cash Flow | 53.02M | 16.46M | (4.8M) | 16.99M | 16.23M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 40.84M | (17.08M) | (4.56M) | (7.13M) | 3.79M |
| Free Cash Flow | (12.18M) | (33.53M) | 240K | (9.13M) | (12.44M) |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.